Alicia K. Morgans, MD, MPH, presented “M0 CRPC: Treatment Options and Emerging Concepts” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.
How to cite: Morgans, Alicia K. “M0 CRPC: Treatment Options and Emerging Concepts” September 13th, 2019. Accessed Jul 2024. https://grandroundsinurology.com/m0-crpc-treatment-options-and-emerging-concepts/
M0 CRPC: Treatment Options and Emerging Concepts – Summary:
Alicia K. Morgans, MD, MPH, Associate Professor of Medicine in Hematology and Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the use of androgen receptor antagonists in treating patients with non-metastatic (M0) castrate-resistant prostate cancer (CRPC). She goes on to discuss how before these three pivotal trials, treatment for patients with M0 CRPC remained a bit of a mystery. However, the results of these trials demonstrated treating men with these agents who had a PSA doubling time less than ten months significantly improved their metastasis-free survival compared to men in the control arm.
About The 5th Annual Prostate & Urologic Cancer Symposium:
The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Morgans presented this lecture during the 5th iteration of this summit in 2019. Other presentations from this symposium include:
MRI First: The Role of MRI in Biopsy Naïve Patients
Expanding the Role of Surgical Management of High-Risk Prostate Cancer
ABOUT THE AUTHOR
Alicia K. Morgans is an Associate Professor of Medicine (Hematology and Oncology) at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine in Chicago, where she provides clinical care and does research in genitourinary malignancies. Dr. Morgans received her MD from the University of Pennsylvania in 2006. She then completed her internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania in 2009, and her fellowship in Hematology-Oncology at the Dana-Farber Cancer Institute in 2012. In 2015, Dr. Morgans received her MPH from Vanderbilt University School of Medicine. Since 2004, her work on a myriad of important uro-oncological topics has been included in such publications as Urology, European Urology, Prostate, and Cancer Medicine. She is also on the Editorial Board of the Journal of Clinical Oncology. Additionally, she is currently leading three active clinical trials.
